ArticleOrphanet journal of rare diseases2026
Real world data from the Heidelberg Registry of Chronic Singultus (HeReChroS).
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHiccups lasting more than one month ("chronic singultus") is a rare disease that impairs quality of life. Its low prevalence hampers evidence generation. The new Heidelberg Registry of Chronic Singultus (HeReChroS) aims to gather epidemiological data, assess disease burden, identify care gaps, improve treatment, and contribute to a more precise clinical characterization of the disease. This analysis of real-world data seeks to characterize the current HeReChroS patient cohort.
methodsThe routinely collected data of patients with chronic singultus (ICD 10: G25.3) from October 2022 to March 2025 were retrospectively entered into HeReChroS. Descriptive statistics were calculated on data of the initial visit, including demographics, medical history, and patient-reported outcomes (PROs) such as disease burden and well-being.
resultsA total of 131 patients were included (104 male, 27 female). Common symptoms alongside hiccups included fatigue (90%), sleep disorders (80%), and concentration difficulties (70%). Comorbidity frequency was high (median 3, IQR 2, range 0-9, mode 2 comorbid organ systems), with gastrointestinal (75%), vascular (52%), and pulmonary (28%) conditions most common. Well-being was markedly reduced (mean 35.3, SD 22, range 0-90, on a 0-100 scale). Screening questionnaires suggested that 42% of patients were depressed, and 15% of patients reported suicidal thoughts.
conclusionHeReChroS offers a large dataset of patients with chronic singultus, enabling in-depth analysis of this rare disease. Quality of life is markedly impaired, and management remains challenging. Expanding the registry across countries and languages would enhance the statistical power and generalizability. German Clinical Trials Registry (Number: DRKS00033956, 25 March 2024, URL: https://www.drks.de/DRKS00033956 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.